Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK4 | Q13043 | 18/20 | 0.63 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.61 |
| ▸ | AURKA | O14965 | 1/20 | 0.61 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.61 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.61 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.61 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.61 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.61 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.61 |
| ▸ | STK3 | Q13188 | 1/20 | 0.60 |
| ▸ | PLK1 | P53350 | 1/20 | 0.57 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.57 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22680883 | 0.84 | TNK2 (0.56) | AURKADCLK1MAPK7LRRK2 | |
| SCHEMBL22680705 | 0.82 | DCLK1 (0.52) | AURKADCLK1MAPK7LRRK2AURKB | |
| SCHEMBL22680785 | 0.80 | DCLK1 (0.50) | AURKADCLK1MAPK7LRRK2 | |
| SCHEMBL24687681 | 0.79 | AURKA (0.71) | STK4PIK3CDAURKADCLK1PIK3C2G | |
| SCHEMBL24071125 | 0.78 | STK4 (1.00) | STK4STK3 | |
| SCHEMBL23998755 | 0.78 | STK4 (1.00) | STK4STK3 | |
| SCHEMBL22680895 | 0.78 | LRRK2 (0.51) | DCLK1MAPK7LRRK2 | |
| SCHEMBL23998642 | 0.77 | STK4 (1.00) | STK4STK3 | |
| SCHEMBL23998721 | 0.77 | STK4 (1.00) | STK4STK3 | |
| SCHEMBL23998646 | 0.77 | STK4 (1.00) | STK4STK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279707-B2 | NEK inhibitors and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20200361948-A1 | NEK INHIBITORS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361948-A1 | NEK INHIBITORS AND METHODS OF USE | NEK5, NEK2, NEK1 | STK4 292/4885PIK3CD 2750/4885AURKA 508/4885 |
| US-11279707-B2 | NEK inhibitors and methods of use | NEK5, NEK2, NEK1 | STK4 292/4885PIK3CD 2750/4885AURKA 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.